SurModics (SRDX) Reports Q3 EPS of $0.27, Revenues Beat; 'Raising Fiscal 2018 Revenue & EPS Guidance'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Surmodics Reports Third Quarter Fiscal 2018 Results
August 6, 2018 7:30 AM EDTRaises Fiscal 2018 Revenue Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 third quarter ended June 30, 2018, and updated its financial outlook for fiscal 2018.
Summary of Third Quarter Fiscal 2018 and Recent Highlights
Revenue of $22.2 million, up 24.9% Raising revenue guidance range to $79.0 to $81.0 million GAAP EPS of ($0.20), Non-GAAP EPS of $0.27 Acquisition of thrombectomy... More